• FDA grants marketing authorization for kidneyintelX.dkd to assess risk of progressive kidney function decline in adults with type 2 diabetes and early-stage kidney disease.


  • Renalytix selects Eversana to expand commercialization of KidneyIntelX for early-stage kidney disease prognosis detection in patients with type 2 diabetes.


  • Real-world Utility Data demonstrates KidneyIntelX optimizes clinical management in early-stage CKD across physician specialities.